

removed by prior streaking on selective plates, resulting in a sample containing little or no target DNA for molecular analysis.

In summary, the results of this study indicate that direct DNA release through bacterial lysis, combined with the addition of  $\geq 2 \mu\text{g}$  BSA, represents an effective system for the RT-PCR detection of MRSA from screening swabs, and potentially could be applied to similar pathogen transport systems. In addition, the authors suggest that equipment used for specimen collection, transport and processing should be accessed and optimised for RT-PCR assays. □

## References

- Cunningham R, Jenks P, Northwood J, Wallis M, Ferguson S, Hunt S. Effect on MRSA transmission of rapid PCR testing of patients admitted to critical care. *J Hosp Infect* 2006; **65**: 1–5.
- Choudhury RSR, Melles DC, Eadie K *et al*. Direct detection of human *Staphylococcus aureus* carriage in the nose using the Lightcycler *Staphylococcus* kit. *J Microbiol Methods* 2006; **65**: 354–6.
- Huletsky A, Lebel P, Picard FJ *et al*. Identification of methicillin-resistant *Staphylococcus aureus* carriage in less than one hour during a hospital surveillance programme. *Clin Infect Dis* 2005; **40**: 976–81.
- Paule SM, Pasquariello AC, Hacek DM *et al*. Direct detection of *Staphylococcus aureus* from adult and neonate nasal swab specimens using real-time polymerase chain reaction. *J Mol Diagn* 2004; **6**: 191–6.
- Wilson IG. Inhibition and facilitation of nucleic acid amplification. *Appl Environ Microbiol* 1997; **63**: 3741–51.
- Cloud JL, Hymas W, Carroll KC. Impact of nasopharyngeal swab types on detection of *Bordetella pertussis* by PCR and culture. *J Clin Microbiol* 2002; **40**: 3838–40.
- Wadowsky RM, Laus S, Libert T, States SJ, Ehrlich GD. Inhibition of PCR-based assay for *Bordetella pertussis* by using calcium alginate fiber and aluminum shaft components of a nasopharyngeal swab. *J Clin Microbiol* 1994; **32**: 1054–7.
- Gibb AP, Wong S. Inhibition of PCR by agar from bacteriological transport media. *J Clin Microbiol* 1998; **36**: 275–6.
- Ünal S, Hoskins J, Flokowitsch JE *et al*. Detection of methicillin-resistant staphylococci by using the polymerase chain reaction. *J Clin Microbiol* 1992; **30**: 1685–91.
- Al-Soud WA, Rådström P. Effects of amplification facilitators on diagnostic PCR in the presence of blood, feces and meat. *J Clin Microbiol* 2002; **38**: 4463–70.
- Jiang J, Alderisio KA, Singh A, Xiao L. Development of procedures for direct extraction of *Cryptosporidium* DNA from water concentrates and for relief of PCR inhibitors. *Appl Environ Microbiol* 2005; **71**: 1135–41.
- Vadrot C, Bex V, Mouilleseaux A, Squinazi F, Darbord JC. Detection of *Mycobacterium tuberculosis* complex by PCR in hospital air samples. *J Hosp Infect* 2004; **58**: 262–7.
- Moppett J, van der Velden VHI, Wijkhuijs AJM, Hancock J, van Dongen JJM, Gouden N. Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin. *Leukemia* 2003; **17**: 268–70.
- Giambernardi TA, Rodeck U, Klebe RJ. Bovine serum albumin reverses inhibition of RT-PCR by melanin. *Biotechniques* 1998; **25**: 564–6.
- Kreider CA. Relief of amplification inhibition in PCR with bovine serum albumin or T4 gene 32 protein. *Appl Environ Microbiol* 1996; **62**: 1102–6.
- Cruickshank R. *Medical microbiology: a guide to the laboratory diagnosis and control of infection* 11th edn. London: Livingstone, 1969: 871–2.
- Grisold AJ, Leitner E, Mühlbauer G, Marth E, Kessler HH. Detection of methicillin-resistant *Staphylococcus aureus* and simultaneous confirmation by automated nucleic acid extraction and real-time PCR. *J Clin Microbiol* 2002; **40**: 2392–7.
- Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acids reveals an asymmetrical distribution of binding sites. *Nat Struct Biol* 1998; **5**: 827–35.

## Prevalence of *Salmonella typhi* among food handlers from bukbas in Nigeria

S. I. SMITH<sup>1</sup>, F ALAO<sup>1</sup>, H. T. GOODLUCK<sup>1</sup>, M. FOWORA<sup>2</sup>, M. BAMIDELE<sup>2</sup>, E. OMONIGBEHIN<sup>2</sup> and A. O. COKER<sup>1</sup>

<sup>1</sup>Molecular Biology and Biotechnology Division, Nigerian Institute of Medical Research; and <sup>2</sup>College of Medicine, University of Lagos, Nigeria

*Salmonella enterica* serovar *typhi* is the aetiological agent of typhoid fever and causes an estimated 16.6 million cases and 600,000 deaths worldwide each year. A syndrome similar to typhoid fever is caused by paratyphoid serotypes of *Salmonella* species.<sup>1</sup>

*Salmonella typhi* is transmitted through food or water contaminated with faeces from infected persons, persistent excretors or from chronic asymptomatic carriers who handle food. Humans are the only host for *S. typhi* and there are no known environmental reservoirs.<sup>1,2</sup> Typhoid fever remains a major public health problem in many developing countries.<sup>2</sup> It is a sporadic disease in developed countries, occurring mainly in travellers returning from overseas. It can also produce the occasional point-source epidemic.<sup>3</sup>

In endemic areas, identified risk factors for the disease include eating food prepared outside the home (e.g., ice cream, flavoured iced drinks) by street vendors,<sup>4</sup> drinking contaminated water,<sup>5</sup> close contact with an infected person,<sup>6</sup> poor housing with inadequate facilities for personal hygiene,<sup>7</sup> and the recent use of antimicrobial drugs.<sup>4</sup>

Typhoid fever is among the major widespread diseases affecting the population in Nigeria and has been rated eighth among these common infections.<sup>8</sup> Nigeria, like many other tropical and developing countries, has been described as an endemic zone for typhoid fever.<sup>9,10</sup>

In Nigeria, transmission of typhoid fever occurs all year round but rates are slightly higher in April and July, coinciding with the height of the hot, dry season and the onset of the rainy season, respectively.<sup>11</sup> The highest number of cases of typhoid fever are recorded during the rainy season in south-east Nigeria.<sup>10</sup> Typhoid fever has been reported in all age groups and classes in Nigeria.<sup>12</sup> Owing to the irregular nature of bacterial shedding, several samples

Correspondence to: Dr. S. I. Smith

Molecular Biology and Biotechnology Division, Nigerian Institute of Medical Research, P. M. B. 2103, Yaba, Lagos, Nigeria.

Email: stellaismith@yahoo.com

**Table 1.** Antibiotic sensitivity pattern of *Salmonella typhi* and other isolates obtained from stool and water samples.

	AM (10 µg)	COT (25 µg)	CHL (30 µg)	NAL (30 µg)	OFL (30 µg)	CIP (5 µg)	TET (30 µg)
<i>S. typhi</i> (n=3)	R	3 (100%)	1 (33.3%)	3 (100%)	3 (100%)	3(100%)	1 (33.3%)
<i>S. choleraesuis</i> (n=1)	R	R	R	1 (100%)	1 (100%)	1(100%)	1 (100%)
<i>S. enteritidis</i> (n=3)	R	2 (66.7%)	R	3 (100%)	3 (100%)	3(100%)	2 (66.7%)

AM: ampicillin, COT: cotrimoxazole, CHL: chloramphenicol, NAL: nalidixic acid, OFL: ofloxacin, CIP: ciprofloxacin, TET: tetracycline.

should be examined in order to identify carriers.<sup>13</sup>

Up to 10% of convalescing patients with untreated typhoid excrete *S. typhi* in faeces for up to three months, while 1–4% become long-term carriers, excreting the organism for more than a year. Furthermore, up to 25% of long-term carriers have no history of typhoid. Chronic carriage is more common among women and the elderly and in patients with cholelithiasis.<sup>14</sup>

Excretion of *Salmonella* species by humans may continue long after clinical cure. Approximately 5% of patients cured of typhoid fever remain carriers for months or even years. Antibiotics are usually ineffective in eradicating carriage (even if the organism is susceptible) because the site of carriage may not allow penetration by the antibiotic agent.<sup>15,16</sup>

The main aim of this pilot study is to establish the prevalence and plasmid profile of *S. typhi* in healthy food handlers in bukkas (local fast-food restaurants) in Lagos. This is the first report on typhoid carriage among this group in Nigeria.

A total of 53 stool samples and 36 water samples (used in the preparation of foods and for drinking) were collected from different apparently healthy food handlers in June and July 2006. The samples were collected in leak-proof containers and were transported to the molecular biology and biotechnology laboratory of the Nigerian Institute of Medical Research within an hour of collection for processing. The food handlers were not on antibiotic therapy.

The samples comprised 13 stools and 10 water samples from the Oshodi area, three stools and two water samples from Ojuelegba, nine stools and four water samples from Yaba, 11 stools and six water samples from Ketu, and 17 stools and 14 water samples from the Mafoluku area. All samples were collected in duplicate.

A loop of stool sample was inoculated aseptically in a McCartney bottle containing 9 mL selenite F broth. One water sample was measured aseptically into a McCartney

bottle containing 5 mL selenite F broth. These were incubated at 37°C for 24 h and then streaked on Salmonella–Shigella agar and incubated for 24 h at 37°C. The isolates were identified and characterised using the method of Cowan.<sup>16</sup>

The NCCLS disc-diffusion method<sup>1</sup> was used for antimicrobial susceptibility testing. Antimicrobial discs tested included ampicillin (10 µg), cotrimoxazole (25 µg), chloramphenicol (30 µg), gentamicin (10 µg), nalidixic acid (30 µg), ofloxacin (30 µg), co-amoxycylav (30 µg) tetracycline (30 µg) and ciprofloxacin (5 µg).

Plasmid DNA isolation was performed using the alkaline lysis method of Birnboim and Doly.<sup>17</sup> Results were analysed statistically using the  $\chi^2$  test.

*Salmonella* spp. (three *S. typhi* [5.7%], three *S. enteritidis* [5.7%] and one *S. choleraesuis* (1.9%)) were recovered from seven (13.2%) of the 53 stool samples processed. None of the water samples yielded a *Salmonella* sp. Table 1 shows the antibiotic sensitivity pattern of the isolates. Table 2 shows the different molecular weights of plasmids carried by the *Salmonella* species isolated.

In this study, the prevalence of *S. typhi* among healthy food handlers in Lagos was 5.7%. It has been reported that food vendors are carriers of a variety of bacterial enteropathogens, including *S. typhi*.<sup>18</sup> This study confirms this finding.

Inadequate personal hygiene can facilitate the transmission of these pathogens via food to humans. The serving stage is a critical point in the street food industry<sup>19</sup> because enteropathogens can survive on the hands for over three hours.<sup>20</sup> Therefore, carriers of *S. typhi* and other *Salmonella* species who handle food in bukkas may pose a risk to their customers.

The major sources of water for the food handlers were public tap water and bore hole water. According to Nickerson and Sinskey,<sup>21</sup> *Salmonella* spp. do not multiply significantly in the natural environment, but they can survive for weeks in water and for several years in soil if

**Table 2.** Molecular weight of plasmids harboured by *Salmonella typhi* and other *Salmonella* species.

C/N	Sample number	Isolate	Number of plasmids	Molecular weight (kb)
2	S03	<i>S. typhi</i>	2	14.125, 35.481
3	S10	<i>S. enteritidis</i>	0	None
4	S22	<i>S. typhi</i>	1	14.125
5	S37	<i>S. typhi</i>	2	14.125, 35.481
6	S43	<i>S. choleraesuis</i>	3	14.125, 56.234, 35.481
7	S45	<i>S. enteritidis</i>	3	14.125, 56.234, 35.481
8	S51	<i>S. enteritidis</i>	2	14.125, 35.481

temperature, humidity and pH are favourable. It can be concluded that the carriers of *S. typhi* and other *Salmonella* species probably did not acquire the microorganisms from the water used for drinking and in food preparation.

Ampicillin, chloramphenicol and tetracycline are used as first-line treatment in typhoid fever. The high resistance to these agents corroborates the findings of Olukoya *et al.*<sup>22</sup> and Smith *et al.*,<sup>23</sup> who showed that easy access to drugs has led to increasingly resistant strains.

The findings of this study agree with those of Chukwuani *et al.*,<sup>24</sup> who showed that the quinolones fleroxacin and ciprofloxacin possess greater potential and benefits as first-line therapy for the management of typhoid fever in this environment.

In this study, the three isolates of *S. typhi* that were resistant to ampicillin harboured a plasmid of low molecular weight (14.125 kb), while the two isolates of *S. typhi* resistant to tetracycline harboured plasmids of high molecular weight (35.4 kb).

Plasmids in salmonellas may code for antibiotic resistance; however, this study did not ascertain whether or not the antibiotic resistance was plasmid-mediated.

The rate of resistance or susceptibility to a particular antibiotic depends not only on the plasmid harboured but also on the rate of exposure to these antibiotics. Therefore, the high rate of multidrug resistance demonstrated by these isolates would seem to make a case for the appropriate use of drugs in this environment.

It should be noted that the number of isolates studied here was low; however, these preliminary findings indicate the need to implement environmental laws covering food preparation and sanitation.

The high level of multidrug-resistant *Salmonella* species indicates a need for appropriate measures in managing typhoid fever and its complications. Furthermore, the antibiotics used in health institutions to control enteric infections should be reviewed periodically.

In view of the high incidence of typhoid fever and antibiotic resistance in Nigeria, typhoid fever vaccination programmes<sup>25</sup> should be implemented, as the new-generation vaccines have been found to be very effective and relatively inexpensive. However, the fluoroquinolone antibiotics remain the drug of choice for the management of typhoid fever in this environment. □

*SIS would like to acknowledge the support of a grant (no E/4020-1) from IFS and also the support of Mrs. Akinola for coordinating the food handlers in the Oshodi/Mafoluku area.*

## References

- World Health Organization. *Manual for the laboratory identification and antimicrobial susceptibility testing of bacterial pathogens of public health importance in the developing world*. Geneva: WHO, 2003.
- World Health Organization. *Vaccines, immunization and biologicals*. [www.who.int/vaccines.diseases/diseases/typhoid\\_fever.html](http://www.who.int/vaccines.diseases/diseases/typhoid_fever.html).
- Ackers ML, Puhr ND, Tauxe RV, Mintz ED. Laboratory-based surveillance of *Salmonella* serotype *typhi* infections in the United States: antimicrobial resistance on the rise. *JAMA* 2000; **283**: 2668–73.
- Luby SP, Faizan M, Fisher-Hoch SP *et al.* Risk factors for typhoid fever in an endemic setting, Karachi, Pakistan. *Epidemiol Infect* 1998; **120**: 129–38.
- Mermin JH, Villar R, Carpenter J *et al.* A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. *J Infect Dis* 1999; **179**: 1416–22.
- Luxemburger C, Chau MC, Mai NL *et al.* Risk factors for typhoid fever in the Mekong Delta, Southern Vietnam: a case-control study. *Trans R Soc Trop Med Hyg* 2001; **95**: 19–23.
- Gasem MH, Dolmans WM, Keuter MM, Djokomoeljanto RR. Poor food hygiene and housing as risk factors for typhoid fever in Semarang, Indonesia. *Trop Med Int Health* 2001; **6**: 484–90.
- Anonymous. Routine disease reports for 1992. *Niger Bull Epidemiol* 1993; **3**: 19.
- Odugbemi TO, Oduyebo O, Animashaun T. Typhoid fever: microbiological aspects. *Niger Postgrad Med J* 1994; **1**: 39–43.
- Oboegbulam SI, Oguike JU, Gugnanai M. Microbiological studies on cases diagnosed as typhoid/enteric fever in south-east Nigeria. *J Commun Dis* 1995; **27**: 97–100.
- Idoko JA, Anjorin FI, Lawande RV. Typhoid fever in Zaria, northern Nigeria. *Niger Med Pract* 1988; **15**: 21–3.
- Rasaily R, Dutta P, Saha MR, Mitra U, Lahiri M, Pal SC. Multidrug resistant typhoid fever in hospitalized children: clinical, bacteriological and epidemiological profiles. *Eur J Epidemiol* 1994; **10**: 41–6.
- Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. *N Engl J Med* 2002; **347**: 1770–82.
- Levine MM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of *Salmonella typhi* in Santiago, Chile, an endemic area. *J Infect Dis* 1982; **26**: 724–6.
- Todar K. *Salmonella* and salmonellosis. In: *Todar's online textbook of bacteriology*. Madison: University of Wisconsin-Madison, 2005. [www.textbookofbacteriology.net](http://www.textbookofbacteriology.net)
- Barrow GI, Feltham RKA eds. *Cowan and Steel's Manual for the identification of medical bacteria* 3rd edn. Cambridge: University Press, 1993: 94–150.
- Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res* 1979; **7**: 1513–23.
- Mensah P, Owusu-Darko K, Yeboah-Manu D, Ablordey A, Nkrumah FK, Kamiya H. The role of street food vendors in the transmission of enteric pathogens. *Ghana Med J* 1999; **33**: 19–29.
- Mensah P, Yeboah-Manu D, Owusu-Darko K, Ablordey A. Street foods in Accra, Ghana: how safe are they? *Bull WHO* 2002; **80**: 546–54.
- Mensah P. Persistent diarrhoea in Ghana. Report submitted to Japan International Cooperation Agency. 1997.
- Nickerson JT, Sinskey AJ. Food infections: salmonellosis. In: *Microbiology of foods and food processing*. London: Elsevier, 1972: 197–213.
- Olukoya DK, Smith SI, Eytayo CA, Ogunjimi A. Drug resistance and plasmid profile of *Salmonella* species isolated from different sources in Nigeria. *Afr J Clin Exp Microbiol* 2000; **1**: 21–7.
- Smith SI, Odunukwe NN, Niemogha MT *et al.* Typhoid fever in Nigeria: analysis of phenotypic and genotypic methods of *Salmonella typhi* identification. *Res J Biotechnol* 2006; **1**: 17–21.
- Chukwuani CM, Onyemelukwe GC, Okonkwo PO, Coker HA, Ifudu ND. Fleroxacin vs. ciprofloxacin in the management of typhoid fever: a randomized, open, comparative study in Nigerian patients. *Clin Drug Investig* 1998; **16**: 279–88.
- World Health Organization. Typhoid Immunization Working Group. Background paper on vaccination against typhoid fever using new-generation vaccines. Presented at the SAGE November 2007 meeting. 2007;: 1–67.